

## AMENDMENTS TO THE CLAIMS

The listing of claims below replaces all previous versions.

- 1-26. (Canceled)
27. (Currently amended) A linear single chain recombinant tri-specific antibody scTsAb comprising in tandem an anti-Carcinoma-Embryonic Antigen single chain variable fragment of the tri-specific antibody, an Fc linking peptide, an anti-CD3 single chain variable fragment, a human serum albumin linking peptide, and an anti-CD28 single-domain antibody fragment ~~The linear single chain recombinant tri-specific antibody of claim 21,~~ wherein the anti-Carcinoma-Embryonic Antigen single chain ~~antigen-antibody~~ variable fragment comprises the amino acid sequence set forth in SEQ ID NO: 1.
- 28-30. (Canceled)
31. (Currently amended) The linear single chain recombinant tri-specific antibody of claim ~~[[21]]27~~, wherein the anti-CD28 single-domain antibody fragment comprises the amino acid sequence set forth in SEQ ID NO: 3.
32. (Currently amended) The linear single chain recombinant tri-specific antibody of claim ~~[[21]]27~~ comprising the amino acid sequence of SEQ ID NO: 4.
33. (Currently amended) The linear single chain recombinant tri-specific antibody of claim ~~[[21]]27~~, wherein the antibody is purified.
34. (Withdrawn) A DNA sequence encoding the single chain tri-specific antibody of

claim 21.

35. (Withdrawn) The DNA sequence of claim 33, comprising the nucleic acid sequence of SEQ ID NO: 3.
36. (Withdrawn) An expression vector comprising the DNA sequence of claim 33.
37. (Withdrawn) The expression vector of claim 35 comprising the DNA sequence of claim 33 and pTRI.
38. (Withdrawn) A host cell comprising the expression vector of claim 35.
39. (Withdrawn) A method for producing a single chain tri-specific antibody comprising culturing the host cell of claim 37 such that the DNA sequence encoding the single chain tri-specific antibody is expressed, and purifying said single chain tri-specific antibody.
40. (Withdrawn) A method for treating or preventing a cancer that expresses carcinogenic embryonic antigen, said method comprising administering a pharmaceutical composition comprising a purified single chain tri-specific antibody of claim 25.
41. (New) The linear single chain recombinant tri-specific antibody of claim 27, further comprising (i) a c-myc tag (SEQ ID NO: 56), (ii) a (His)<sub>6</sub> tag (SEQ ID NO: 57), or (iii) a c-myc tag (SEQ ID NO: 56 and a (His)<sub>6</sub> tag (SEQ ID NO: 57), in the carboxy terminal region of the single chain tri-specific antibody.

Amendment and Response to Final Office Action  
U.S. Serial No.: 10/594,908  
Filing Date: January 8, 2009  
Attorney Docket No. BABT-001US

42. (New) The linear single chain recombinant tri-specific antibody of claim 27, wherein the Fc linking peptide comprising the amino acid sequence set forth in SEQ ID NO: 53.
43. (New) The linear single chain recombinant tri-specific antibody of claim 27, wherein human serum albumin linking peptide comprising the amino acid sequence set forth in SEQ ID NO: 54.